Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + sonidegib
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The combination of pembrolizumab and sonidegib is an investigational therapy for advanced solid tumors. Pembrolizumab is a monoclonal antibody that targets the programmed death receptor-1 (PD-1), acting as an immune checkpoint inhibitor to help the immune system attack cancer cells. Sonidegib is a small molecule inhibitor of the Hedgehog signaling pathway, which plays a key role in tumor growth and maintenance. The rationale for combining these agents is to simultaneously target tumor cell signaling and enhance anti-tumor immunity, potentially offering improved efficacy over standard treatments[4][3][1]. Clinical trials are ongoing to determine optimal dosing, safety, and efficacy in various advanced cancers.
- Other names
- pembrolizumab and sonidegibKeytruda plus Odomzo
02
Targets
SMO (Smoothened)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + sonidegib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + sonidegib.